trending Market Intelligence /marketintelligence/en/news-insights/trending/oj6hubkrrrvuud1cvyu10a2 content esgSubNav
In This List

J&J exec becomes Celgene's new CFO; Portola Pharmaceuticals CEO to retire

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


J&J exec becomes Celgene's new CFO; Portola Pharmaceuticals CEO to retire

S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech and life sciences companies.

* Celgene Corp. said its CFO Peter Kellogg will step down from his position and will be replaced by former Johnson & Johnson executive David Elkins. Kellogg will become executive vice president and chief corporate strategy officer until his retirement in mid-2019.

* Bruker Corp. appointed Gerald Herman CFO. He joined Bruker in 2016 as vice president and corporate controller and was named interim CFO in March.

* Portola Pharmaceuticals Inc. said William Lis will retire as CEO and a board member Aug. 1. Executive Vice President John Curnutte and CFO Mardi Dier will be co-presidents in addition to their current roles on an interim basis. The company has initiated a search to find a suitable replacement.

* Advanced Proteome Therapeutics Corp. appointed Bill Dickie CEO, president and director. The appointment comes after Randal Chase resigned as president, CEO and director of the biotechnology company in April.

* Advaxis Inc. appointed Molly Henderson executive vice president and CFO.

* Tenax Therapeutics Inc. appointed Anthony DiTonno CEO, effective June 1. Michael Jebsen, the company's current interim CEO and CFO, will continue as CFO after DiTonno's appointment.

* Collegium Pharmaceutical Inc. said Joseph Ciaffoni will be promoted to CEO and will join the board, effective July 1. Ciaffoni, who will succeed Michael Heffernan as CEO, has been the company's executive vice president and COO since joining the company in May 2017.

* IsoRay Inc. said Thomas LaVoy resigned as chairman and CEO. Lori Woods will become the company's CEO on an interim basis and Mick McCormick will be board chairman.

* UroGen Pharma Ltd. tapped Stephen Mullennix to replace Gary Titus as CFO on an interim basis. Mullennix, who is the COO of the company, has actively led or participated in more than $3 billion worth of M&A, equity and debt financing transactions, UroGen said in a statement.

* Zai Lab Ltd. appointed William Liang its chief commercial officer.

* TG Therapeutics Inc. appointed Adam Waldman its chief commercial officer.

* Acasti Pharma Inc. appointed Brian Groch chief commercial officer.

* Depomed Inc. appointed Phillip Donenberg CFO and senior vice president, effective July 16. Donenberg will succeed August Moretti, who has served as Depomed's CFO since January 2012.

* Oxford BioMedica PLC said Peter Nolan plans to retire as chief business officer and director of the gene and cell therapy company, effective July 1.

* Kuros Biosciences AG will propose the appointment of Joost de Bruijn as CEO, along with three independent nonexecutive directors, at its annual general meeting June 14.

* Zafgen Inc. appointed Brian McVeigh chief business officer.

* Arcturus Therapeutics Ltd. reinstated Joseph Payne as president and CEO and Pad Chivukula as COO and chief scientific officer after it reached a settlement with Payne.

* Bavarian Nordic A/S appointed Henrik Juuel as executive vice president and CFO. Juuel plans to join the Danish company in the fourth quarter of 2018. He is the CFO of Orexo AB (publ), a specialty pharmaceutical company based in Sweden.

* Mesoblast Ltd. appointed Josh Muntner to the position of CFO. Muntner, who will be based in New York, replaces outgoing CFO Paul Hodgkinson.